Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 740

Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA

Dr Rashmi Murthy speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the recent results from the HER2CLIMB study, which investigated the use of tucatinib in combination with capecitabine and trastuzumab versus placebo, in patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases.

She highlights that there is no single regimen that is considered as the standard of care, and there are very limited treatment options for patients with brain metastases.

Dr Murthy outlines the trial design and results from this study, which found that the combination of tucatinib, capecitabine and trastuzumab reduced the risk of death by a third.

She also discusses the management of patients with brain metastases and their representation in clinical trials.

Read more about the study here


Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation